PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
NCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.
Transl Psychiatry. 2023 Jun 23;13(1):223. doi: 10.1038/s41398-023-02516-0.
The association between antidepressant continuation during pregnancy and postpartum mental health in women with obsessive-compulsive disorder (OCD) is uncertain. We identified 1317 women with live-birth singleton pregnancies and having outpatient/inpatient visits for OCD in the 4 years pre-pregnancy from the Danish registries. We defined three groups based on antidepressant prescriptions filled in the 2 years before pregnancy to delivery: (i) unexposed (n = 449); (ii) discontinuers (n = 346), i.e., with pre-pregnancy antidepressant fills only; (iii) continuers (n = 522), i.e., with antidepressant fills before and during pregnancy. We estimated crude and propensity score weighted hazard ratio (HRs) of postpartum visit for OCD and mood/anxiety disorders using Cox proportional hazard models. In weighted analyses, we found no difference in the probability of a postpartum visit for OCD or MADs with antidepressant continuation compared to unexposed and discontinuers. The likelihood of a postpartum OCD visit was higher in pregnancies having only one prescription fill during pregnancy compared to unexposed (HR = 3.44, 95% CI: 1.24, 9.54) or discontinuers (HR = 2.49, 95% CI: 0.91, 6.83). Continuers in pregnancy without antidepressant fill in the first three months postpartum had higher probability for postpartum visit for mood/anxiety disorders compared to discontinuers (HR = 3.84, 95% CI: 1.49, 9.92). Among pregnant women with pre-existing OCD, we found similar probabilities of a postpartum visit for OCD or mood/anxiety disorders in antidepressant continuers compared to unexposed and discontinuers. Continuers with a single prescription fill during pregnancy or no fill postpartum may have higher risks for these outcomes. Our findings highlight the importance of continuity of treatment throughout the perinatal period.
在患有强迫症 (OCD) 的女性中,怀孕期间继续使用抗抑郁药与产后心理健康之间的关联尚不确定。我们从丹麦登记处确定了 1317 名有活产单胎妊娠且在怀孕前 4 年有门诊/住院 OCD 就诊的女性。我们根据怀孕前 2 年至分娩期间的抗抑郁药处方情况将她们分为三组:(i) 未暴露组(n=449);(ii) 停药组(n=346),即只有怀孕前的抗抑郁药处方;(iii) 继续治疗组(n=522),即怀孕前和怀孕期间都有抗抑郁药处方。我们使用 Cox 比例风险模型估计产后 OCD 和心境/焦虑障碍就诊的粗率和倾向评分加权风险比 (HR)。在加权分析中,我们发现与未暴露组和停药组相比,继续使用抗抑郁药与产后 OCD 或 MADs 的就诊率无差异。与未暴露组(HR=3.44,95%CI:1.24,9.54)或停药组(HR=2.49,95%CI:0.91,6.83)相比,怀孕期间只有一次处方的妊娠产后 OCD 就诊的可能性更高。怀孕期间没有在前三个月内服用抗抑郁药的继续治疗者产后就诊心境/焦虑障碍的可能性高于停药者(HR=3.84,95%CI:1.49,9.92)。在患有既往 OCD 的孕妇中,我们发现继续治疗者产后 OCD 或心境/焦虑障碍就诊的可能性与未暴露组和停药组相似。怀孕期间只有一次处方或产后没有处方的继续治疗者可能有更高的这些结局风险。我们的研究结果强调了在围产期全程治疗连续性的重要性。